You are here: Industry Insights > lupin

News List

Lupin gets tentative USFDA nod for empagliflozin and metformin hydrochloride ER tablets expresspharma
January 08, 2021
They are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
Lupin gets US FDA approval for Sulfamethoxazole and Trimethoprim expresspharma
January 07, 2021
Lupin has received the United States Food and Drug Administration approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL.
Lupin launches Mycophenolate Mofetil Tablets USP expresspharma
December 30, 2020
They are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants.
Lupin launches Meloxicam Capsules expresspharma
December 29, 2020
Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (US FDA).
Lupin gets tentative approval from USFDA for Efinaconazole Topical Solution expresspharma
December 28, 2020
It is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Lupin gets US FDA approval for Rufinamide Oral Suspension expresspharma
December 22, 2020
It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in paediatric patients one year of age and older, and in adults.
Lupin gets US FDA approval for Colesevelam Hydrochloride Tablets expresspharma
December 21, 2020
They are indicated for reducing elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
Lupin gets US FDA approval for Penicillamine Tablets expresspharma
December 02, 2020
They are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis.
Lupin launches Tacrolimus Capsules USP expresspharma
November 26, 2020
They are indicated for the prophylaxis of organ rejection in combination with other immunosuppressants.
Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis pharmaceutical-business-review
November 18, 2020
Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 19 20 Next page